STDAF News 40.6000 Stada Arzneimi Namen (STDAF)
Post# of 273311
Posted On: 04/16/2014 4:00:00 PM
Stada Arzneimi Namen (STDAF) 40.6000 $STDAF
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018
M2 - Mon Apr 14, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rhkdb/biosimilars) has announced the addition of the "Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018" report to their offering. The global market is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and 2018. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone, whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Recombinant peptide market is divided into Calcitonin and Glucagon. Of all the segments, the key traction segment that is estimated to grow at a faster rate of 25% by 2018 is the recombinant glycosylated proteins segment. This growth can mainly be attributed to investments by drug manufacturers to develop biosimilar versions of monoclonal antibodies (more than 50 biosimilars of monoclonal antibodies are in the pipeline), the introduction of the new biosimilar drug Ovaleap' (follitropin) to treat infertility, and the growing demand for erythropoietin and monoclonal antibodies to treat cancer. Monoclonal antibody is one of the lucrative markets for drug manufacturers, for x future investment to develop MAb at a large scale and is also estimated to be the fastest growing market at an estimated CAGR of 41.9% from 2013 to 2018. About eight biologic MAb drugs are expected become off-patent products from 2013 to 2018. The drugs that are expected to lose their patent protections are Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis. The three most targeted products for biosimilars are Rituximab, Infliximab, and Adalimumab due to their high worldwide sales and approvals for multiple indications. Various key industry players of the generics market have started working on the manufacturing and clinical trial activities of MAbs. At present, approximately 50 biosimilar MAbs are in the pipeline. Bioexpress Therapeutic (Switzerland) has 16 biosimilar candidates of MAbs that are in the pipeline. The other players that have invested in the production of MAbs are GeneTechno Science (Japan), Celltrion (South Korea), Zydus-Cadila (India), Biocon (India), and Samsung Biologics (South Korea). Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Analysis - Global Biosimilars Market, By Product - Global Biosimilar Market, By Application - Global Biosimilars Service Market - Geographic Analysis - Competitive Landscape - Company Profiles - Actavis, Inc. - Amgen, Inc. - Biocon Ltd. - Celltrion, Inc. - Cipla Ltd. - Dr. Reddy'S Laboratories Ltd. - Emcure Pharmaceuticals Ltd. - Hospira, Inc. - Lg Life Sciences Ltd. - Merck Kgaa - Mylan, Inc. - Ranbaxy Laboratories Ltd. - Roche Holding Ltd. - Sandoz International Gmbh - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd. - Wockhardt Ltd. Visit http://www.researchandmarkets.com/research/8r...iosimilars
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Biosimilar Market Outlook 2018 Report Discusses Major Trends and Drivers in Detail
M2 - Wed Feb 26, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8qpnt/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" report to their offering. The global biosimilars market is at a crucial turning point, as biosimilars are gaining wide acceptance around the world, with regulatory pathways being clearly defined in every region and R&D investments being at an all time high. Several biosimilars have entered the market over the past 2-3 years. In 2008, Merck, one of the big pharma manufacturers, embraced biosimilars. Large scale partnerships to develop biosimilars are also being announced such as those between Samsung and Biogen, Amgen and Watson, Dr. Reddy's and Merck Serano. According to our latest research report, Global Biosimilar Market Outlook 2018, although the current biosimilars market is small, the future looks optimistic with number of innovative biologics going off patent. The report discusses major trends and drivers in detail and the influence they will have on the market. Emerging markets will play the role of a major driver for the biosimilars market, which will be attributed to the local policies and the biosimilar attitude of the regions. The governments in the emerging economies are encouraging the growth of biosimilars by defining clear regulatory pathways. In the report, the author has segmented the biosimilars market into various categories such as EPO (Erythropoietin), HGH (Human Growth Hormone), IFN (Interferon), mAb (Monoclonal Antibody), Insulin and G-CSF (Granulocyte Colony Stimulating Factor). Each market has been analyzed in terms of major approved biosimilars, drug pipeline, and the impact of patent expirations of important biologics. Similarly, major geographies are also discussed. Apart from the most regulated market of Europe, other economies such as US, India, China and Korea have been discussed. The regulatory scenario of all the economies has been presented. India, for example, recently announced its much awaited new and simple regulatory guidelines, Guidelines on Similar Biologics. Companies Mentioned: - 3 SBio Inc. - Biocon Limited - Bioton - Celltrion Pharm Inc. - Dong-A Pharmaceutical Co., Ltd - Dr.Reddy's Labs (DRL) - Hexal AG - Hospira - Intas Pharmaceuticals Ltd. - LG Life Sciences - Ratiopharm GmbH - Reliance Life Sciences - Sandoz GmbH - Shantha Biotechnics Limited - Stada Arzneimittel - Teva - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/z8...biosimilar About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Viphya Private Secondary School Female Students March to Mzuzu Police Over Sexual Harassment
by Salome Gangire - All Africa Global Media - Sat Feb 15, 4:37AM CST
Viphya Private Secondary School female students Monday morning marched to Mzuzu Police Station to complain about sexual harassment they allegedly face from one of their male teachers.
Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant Peptides
M2 - Thu Jan 30, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/lz28ls/biosimilars) has announced the addition of the "Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant Peptides" report to their offering. The global market is segmented on the basis of products, applications, and services. By product, the global biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further classified into insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Glucagon and calcitonin are considered under the recombinant peptides segment. The recombinant glycosylated proteins segment is the largest segment of the market with a share of 40% of the global market in 2013. Of all the products, monoclonal antibodies will be the fastest-growing segment at an estimated CAGR of 41.9% from 2013 to 2018. Following this, insulin will be the second-fastest growing market from 2013 to 2018.The growth is attributed to the rise in incidences of diabetes; the ongoing patent expiration of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of biosimilars of insulin. By application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure). Oncology is the largest and fastest-growing segment of the global biosimilars market. This is attributed to the increasing prevalence of oncology along with the rise in aging population and the changing lifestyles. The global market will be worth $2.0 billion by 2018, growing at a CAGR of 20.1% during the forecast period (2013 to 2018). The major factors driving the growth of the market are the launch of new biosimilars (monoclonal antibodies, filgrastim, and follitropin); ongoing clinical research on potential pipeline products; patent expirations of various biologics such as Neupogen, Humira, and Lantus; and the increasing demand for first-wave biosimilar products such as somatropin, filgrastim, and erythropoietin. Scope of the Report Product - Recombinant Non-glycosylated Proteins -- Insulin -- Human Growth Hormone -- Granulocyte Colony--stimulating Factor (G--CSF) -- Interferons - Recombinant Glycosylated Proteins -- Erythropoietin -- Monoclonal Antibodies -- Follitropin - Recombinant Peptides -- Glucagon -- Calcitonin Service - Contract Manufacturing Organizations (CMO) - Contract Research Organizations(CRO) - Others (Bioinformatics and Sales & Marketing Services) Application - Oncology - Blood Disorders - Chronic & Autoimmune Diseases - Growth Hormone Deficiency - Infectious Diseases - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Analysis 6 Global Biosimilars Market, By Product 7 Global Biosimilars Market, By Application 8 Global Biosimilars Service Market 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Actavis, Inc - Amgen, Inc - Biocon Ltd - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Emcure Pharmaceuticals Ltd - Hospira, Inc - Lg Life Sciences Ltd - Merck Kgaa - Mylan, Inc - Ranbaxy Laboratories Ltd - Roche Holding Ltd - Sandoz International GMBH (Division Of Novartis International Ag) - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd - Wockhardt Ltd For more information visit http://www.researchandmarkets.com/research/lz...iosimilars
Biosimilars Market by Product & Application - Global Forecast to 2018
M2 - Mon Dec 02, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4ds5k/biosimilars) has announced the addition of the "Biosimilars Market by Product & Application - Global Forecast to 2018" report to their offering. The biosimilar product market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; while the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Calcitonin and glucagon are considered in the recombinant peptides market. The recombinant glycosylated proteins segment is expected to witness the highest growth due to the increased demand for monoclonal antibodies in the treatment for cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. Oncology will be the fastest-growing segment and currently accounts for a 25% market share in the global market in 2013. Following monoclonal antibodies, biosimilars of insulin will be the fastest-growing products and are estimated to grow at a CAGR of 35.6% from 2013 to 2018. The growth is attributed to the rise in incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of the biosimilars of insulin. The global market is highly consolidated with the top three players, namely, Sandoz (Germany), Hospira (U.S.), and Teva (Israel) accounting for approximately 90% of the market share. Other notable players in the market include Dr. Reddy's Laboratories (India), Biocon Ltd. (India), Mylan (U.S.), Biopartners (Switzerland), Amgen (U.S.), and IntasBiopharmaceutical Ltd. (India). The competitive landscape covers the growth strategies adopted by the industry players in the last three years. The company profiles comprise of the basic views on the key players in the biosimilars market and the product portfolios, developments, and strategies adopted to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful. This study covers the revenue market of recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptidesthe three major drug classes of the market. The sales revenue of each biosimilar drug was considered to estimate the global market. The market revenue for each therapeutic area was calculated based on the type of drugs used to treat a particular disease. The market share of the key players involved in manufacturing and commercializing biosimilar products was considered to estimate the market. Key Topics Covered: Introduction Executive Summary Premium Insights Market Overview Industry Analysis Global Biosimilars Market, By Product Global Biosimilars Market, By Application Global Biosimilars Service Market Geographic Analysis Competitive Landscape Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* *Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies. List of Tables (80 Tables) List of Figures (80 Figures) Companies Mentioned - Actavis, Inc - Amgen, Inc - Biocon Ltd - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Emcure Pharmaceuticals Ltd - Hospira, Inc - Lg Life Sciences Ltd - Merck Kgaa - Mylan, Inc - Ranbaxy Laboratories Ltd - Roche Holding Ltd - Sandoz International GMBH (Division Of Novartis International Ag) - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd - Wockhardt Ltd For more information visit http://www.researchandmarkets.com/research/x4...iosimilars About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3M Licenses Fentanyl Transdermal Patch Technology to STADA Arzneimittel AG
Business Wire - Tue Nov 19, 12:05PM CST
3M Drug Delivery Systems announced today that STADA Arzneimittel AG has become the latest drug company to license 3M's patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl. Terms of the license agreement were not disclosed.
Global Biologic Drugs Market to Jump to Over $220 Billion by 2019 says Latest Report
M2 - Tue Aug 13, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jhrbjc/biologics_and) has announced the addition of the "Biologics and Biosimilars World Markets" report to their offering. 1024x768 Normal 0 false false false Biologics, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the biologic drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular diseases, infertility and cystic fibrosis. Globally, the U.S. commands 43% of biologics sales, followed by the E.U. (21%) and Japan (9%). The "Expanding Markets for Biologics and Biosimilars" report covers key biologic and biosimilar drugs, including: - Humira (Adalimumab) - Remicade (Infliximab) - Lantus (Insulin Glargine) - Levemir (Insulin Detemir) - Privigen (Immune Globulin Intravenous) - Perjeta (Pertuzumab) - Soliris (Eculizumab) - Eylea (Aflibercept) - Revlimid (Lenalidomide) - Herceptin (Trastuzumab) - Gardasil - Varivax (Varicella Virus Vaccine Live) - Gammagard Liquid (Immune Globulin Infusion (Human)) - Aranesp (Darbepoetin Alfa) - Enbrel (Etanercept) - Epogen/Procrit/Eprex/Erypo (Epoetin Alfa) - Genotropin (Somatropin) - Herceptin (Trastuzumab) - Humira (Adalimumab) - Neulasta (Pegfilgrastim) - Neupogen (Filgrastim) - Remicade (Infliximab) - Rituxan/MabThera (Rituximab) Biologics and Biosimilars" report examines companies manufacturing biologic and biosimilar equipment and supplies in the world. Companies covered include: - AbbVie, Inc - Abbott Laboratories - Actelion Ltd - Amgen, Inc - Amoytop Biotech Co, Ltd - Anhui Anke Biotechnology (Group) Co, Ltd - Apotex, Inc - Astellas Pharma, Inc - AstraZeneca - Bayer AG - Beijing Four Rings Biopharmaceuticals - Bharat Serums and Vaccines Limited - Bio, Inc - Biocon Ltd - Biogen Idec, Inc - Bioton SA - Boehringer Ingelheim Pharmaceuticals, Inc - Bristol-Myers Squibb, Co - Celgene Corporation - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Elan Corporation, PLC - Eli Lilly & Co - Gideon Richter - Gilead Sciences, Inc - GlaxoSmithKline PLC - Hospira, Inc - Intas Pharmaceuticals Limited - Johnson & Johnson - Merck & Co, Inc - Mylan, Inc - Novartis AG - Pfizer, Inc - Roche Holdings AG - Sandoz International GmbH - Sanofi - Stada Arzneimittel Aktiengesellschaft - Teva Pharmaceutical Industries Limited - Watson Pharmaceuticals, Inc For more information visit http://www.researchandmarkets.com/research/jh...logics_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Corporate Reputation of Pharma in 2012: The Patient Perspective on 29 of the World's Leading Pharma Companies
M2 - Fri May 10, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vttz4c/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma in 2012: The Patient Perspective" report to their offering. A global survey of the views of 600 international, national, and regional patient groups on the corporate reputation of the pharma industry and 29 leading pharma companies Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients, recasting their companies as more patient-centric. PatientView is therefore pleased to ANNOUNCE THE RELEASE of the latest version of its annual review. - A global survey, conducted mid-November to mid-December 2012, exploring the views of 600 international, national, and regional patient groups from 56 countries (72% from Europe) and differing specialties - Patient group feedback on the corporate reputation of the pharma industry during 2012. - Patient group feedback provides rankings of 29 leading pharma companies f
Pharmaceutical Industry in China Report: 2013 Edition
M2 - Tue Apr 16, 5:28AM CDT
Research and Markets has announced the addition of the "Pharmaceutical Industry in China" report to their offering. Aruvian's R'search's report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc. The report also analyzes the Chinese pharmaceutical industry through three frameworks - a SWOT analysis, a PEST analysis, and a Porter's Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China's Pharmaceutical Industry. Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018
M2 - Mon Apr 14, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rhkdb/biosimilars) has announced the addition of the "Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018" report to their offering. The global market is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and 2018. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone, whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Recombinant peptide market is divided into Calcitonin and Glucagon. Of all the segments, the key traction segment that is estimated to grow at a faster rate of 25% by 2018 is the recombinant glycosylated proteins segment. This growth can mainly be attributed to investments by drug manufacturers to develop biosimilar versions of monoclonal antibodies (more than 50 biosimilars of monoclonal antibodies are in the pipeline), the introduction of the new biosimilar drug Ovaleap' (follitropin) to treat infertility, and the growing demand for erythropoietin and monoclonal antibodies to treat cancer. Monoclonal antibody is one of the lucrative markets for drug manufacturers, for x future investment to develop MAb at a large scale and is also estimated to be the fastest growing market at an estimated CAGR of 41.9% from 2013 to 2018. About eight biologic MAb drugs are expected become off-patent products from 2013 to 2018. The drugs that are expected to lose their patent protections are Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin, Synagis, Erbitux, and Lucentis. The three most targeted products for biosimilars are Rituximab, Infliximab, and Adalimumab due to their high worldwide sales and approvals for multiple indications. Various key industry players of the generics market have started working on the manufacturing and clinical trial activities of MAbs. At present, approximately 50 biosimilar MAbs are in the pipeline. Bioexpress Therapeutic (Switzerland) has 16 biosimilar candidates of MAbs that are in the pipeline. The other players that have invested in the production of MAbs are GeneTechno Science (Japan), Celltrion (South Korea), Zydus-Cadila (India), Biocon (India), and Samsung Biologics (South Korea). Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Analysis - Global Biosimilars Market, By Product - Global Biosimilar Market, By Application - Global Biosimilars Service Market - Geographic Analysis - Competitive Landscape - Company Profiles - Actavis, Inc. - Amgen, Inc. - Biocon Ltd. - Celltrion, Inc. - Cipla Ltd. - Dr. Reddy'S Laboratories Ltd. - Emcure Pharmaceuticals Ltd. - Hospira, Inc. - Lg Life Sciences Ltd. - Merck Kgaa - Mylan, Inc. - Ranbaxy Laboratories Ltd. - Roche Holding Ltd. - Sandoz International Gmbh - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd. - Wockhardt Ltd. Visit http://www.researchandmarkets.com/research/8r...iosimilars
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Biosimilar Market Outlook 2018 Report Discusses Major Trends and Drivers in Detail
M2 - Wed Feb 26, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8qpnt/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" report to their offering. The global biosimilars market is at a crucial turning point, as biosimilars are gaining wide acceptance around the world, with regulatory pathways being clearly defined in every region and R&D investments being at an all time high. Several biosimilars have entered the market over the past 2-3 years. In 2008, Merck, one of the big pharma manufacturers, embraced biosimilars. Large scale partnerships to develop biosimilars are also being announced such as those between Samsung and Biogen, Amgen and Watson, Dr. Reddy's and Merck Serano. According to our latest research report, Global Biosimilar Market Outlook 2018, although the current biosimilars market is small, the future looks optimistic with number of innovative biologics going off patent. The report discusses major trends and drivers in detail and the influence they will have on the market. Emerging markets will play the role of a major driver for the biosimilars market, which will be attributed to the local policies and the biosimilar attitude of the regions. The governments in the emerging economies are encouraging the growth of biosimilars by defining clear regulatory pathways. In the report, the author has segmented the biosimilars market into various categories such as EPO (Erythropoietin), HGH (Human Growth Hormone), IFN (Interferon), mAb (Monoclonal Antibody), Insulin and G-CSF (Granulocyte Colony Stimulating Factor). Each market has been analyzed in terms of major approved biosimilars, drug pipeline, and the impact of patent expirations of important biologics. Similarly, major geographies are also discussed. Apart from the most regulated market of Europe, other economies such as US, India, China and Korea have been discussed. The regulatory scenario of all the economies has been presented. India, for example, recently announced its much awaited new and simple regulatory guidelines, Guidelines on Similar Biologics. Companies Mentioned: - 3 SBio Inc. - Biocon Limited - Bioton - Celltrion Pharm Inc. - Dong-A Pharmaceutical Co., Ltd - Dr.Reddy's Labs (DRL) - Hexal AG - Hospira - Intas Pharmaceuticals Ltd. - LG Life Sciences - Ratiopharm GmbH - Reliance Life Sciences - Sandoz GmbH - Shantha Biotechnics Limited - Stada Arzneimittel - Teva - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/z8...biosimilar About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Viphya Private Secondary School Female Students March to Mzuzu Police Over Sexual Harassment
by Salome Gangire - All Africa Global Media - Sat Feb 15, 4:37AM CST
Viphya Private Secondary School female students Monday morning marched to Mzuzu Police Station to complain about sexual harassment they allegedly face from one of their male teachers.
Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant Peptides
M2 - Thu Jan 30, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/lz28ls/biosimilars) has announced the addition of the "Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant Peptides" report to their offering. The global market is segmented on the basis of products, applications, and services. By product, the global biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further classified into insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Glucagon and calcitonin are considered under the recombinant peptides segment. The recombinant glycosylated proteins segment is the largest segment of the market with a share of 40% of the global market in 2013. Of all the products, monoclonal antibodies will be the fastest-growing segment at an estimated CAGR of 41.9% from 2013 to 2018. Following this, insulin will be the second-fastest growing market from 2013 to 2018.The growth is attributed to the rise in incidences of diabetes; the ongoing patent expiration of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of biosimilars of insulin. By application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure). Oncology is the largest and fastest-growing segment of the global biosimilars market. This is attributed to the increasing prevalence of oncology along with the rise in aging population and the changing lifestyles. The global market will be worth $2.0 billion by 2018, growing at a CAGR of 20.1% during the forecast period (2013 to 2018). The major factors driving the growth of the market are the launch of new biosimilars (monoclonal antibodies, filgrastim, and follitropin); ongoing clinical research on potential pipeline products; patent expirations of various biologics such as Neupogen, Humira, and Lantus; and the increasing demand for first-wave biosimilar products such as somatropin, filgrastim, and erythropoietin. Scope of the Report Product - Recombinant Non-glycosylated Proteins -- Insulin -- Human Growth Hormone -- Granulocyte Colony--stimulating Factor (G--CSF) -- Interferons - Recombinant Glycosylated Proteins -- Erythropoietin -- Monoclonal Antibodies -- Follitropin - Recombinant Peptides -- Glucagon -- Calcitonin Service - Contract Manufacturing Organizations (CMO) - Contract Research Organizations(CRO) - Others (Bioinformatics and Sales & Marketing Services) Application - Oncology - Blood Disorders - Chronic & Autoimmune Diseases - Growth Hormone Deficiency - Infectious Diseases - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Analysis 6 Global Biosimilars Market, By Product 7 Global Biosimilars Market, By Application 8 Global Biosimilars Service Market 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Actavis, Inc - Amgen, Inc - Biocon Ltd - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Emcure Pharmaceuticals Ltd - Hospira, Inc - Lg Life Sciences Ltd - Merck Kgaa - Mylan, Inc - Ranbaxy Laboratories Ltd - Roche Holding Ltd - Sandoz International GMBH (Division Of Novartis International Ag) - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd - Wockhardt Ltd For more information visit http://www.researchandmarkets.com/research/lz...iosimilars
Biosimilars Market by Product & Application - Global Forecast to 2018
M2 - Mon Dec 02, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4ds5k/biosimilars) has announced the addition of the "Biosimilars Market by Product & Application - Global Forecast to 2018" report to their offering. The biosimilar product market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; while the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Calcitonin and glucagon are considered in the recombinant peptides market. The recombinant glycosylated proteins segment is expected to witness the highest growth due to the increased demand for monoclonal antibodies in the treatment for cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. Oncology will be the fastest-growing segment and currently accounts for a 25% market share in the global market in 2013. Following monoclonal antibodies, biosimilars of insulin will be the fastest-growing products and are estimated to grow at a CAGR of 35.6% from 2013 to 2018. The growth is attributed to the rise in incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of the biosimilars of insulin. The global market is highly consolidated with the top three players, namely, Sandoz (Germany), Hospira (U.S.), and Teva (Israel) accounting for approximately 90% of the market share. Other notable players in the market include Dr. Reddy's Laboratories (India), Biocon Ltd. (India), Mylan (U.S.), Biopartners (Switzerland), Amgen (U.S.), and IntasBiopharmaceutical Ltd. (India). The competitive landscape covers the growth strategies adopted by the industry players in the last three years. The company profiles comprise of the basic views on the key players in the biosimilars market and the product portfolios, developments, and strategies adopted to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful. This study covers the revenue market of recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptidesthe three major drug classes of the market. The sales revenue of each biosimilar drug was considered to estimate the global market. The market revenue for each therapeutic area was calculated based on the type of drugs used to treat a particular disease. The market share of the key players involved in manufacturing and commercializing biosimilar products was considered to estimate the market. Key Topics Covered: Introduction Executive Summary Premium Insights Market Overview Industry Analysis Global Biosimilars Market, By Product Global Biosimilars Market, By Application Global Biosimilars Service Market Geographic Analysis Competitive Landscape Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* *Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies. List of Tables (80 Tables) List of Figures (80 Figures) Companies Mentioned - Actavis, Inc - Amgen, Inc - Biocon Ltd - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Emcure Pharmaceuticals Ltd - Hospira, Inc - Lg Life Sciences Ltd - Merck Kgaa - Mylan, Inc - Ranbaxy Laboratories Ltd - Roche Holding Ltd - Sandoz International GMBH (Division Of Novartis International Ag) - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd - Wockhardt Ltd For more information visit http://www.researchandmarkets.com/research/x4...iosimilars About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3M Licenses Fentanyl Transdermal Patch Technology to STADA Arzneimittel AG
Business Wire - Tue Nov 19, 12:05PM CST
3M Drug Delivery Systems announced today that STADA Arzneimittel AG has become the latest drug company to license 3M's patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl. Terms of the license agreement were not disclosed.
Global Biologic Drugs Market to Jump to Over $220 Billion by 2019 says Latest Report
M2 - Tue Aug 13, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jhrbjc/biologics_and) has announced the addition of the "Biologics and Biosimilars World Markets" report to their offering. 1024x768 Normal 0 false false false Biologics, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the biologic drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular diseases, infertility and cystic fibrosis. Globally, the U.S. commands 43% of biologics sales, followed by the E.U. (21%) and Japan (9%). The "Expanding Markets for Biologics and Biosimilars" report covers key biologic and biosimilar drugs, including: - Humira (Adalimumab) - Remicade (Infliximab) - Lantus (Insulin Glargine) - Levemir (Insulin Detemir) - Privigen (Immune Globulin Intravenous) - Perjeta (Pertuzumab) - Soliris (Eculizumab) - Eylea (Aflibercept) - Revlimid (Lenalidomide) - Herceptin (Trastuzumab) - Gardasil - Varivax (Varicella Virus Vaccine Live) - Gammagard Liquid (Immune Globulin Infusion (Human)) - Aranesp (Darbepoetin Alfa) - Enbrel (Etanercept) - Epogen/Procrit/Eprex/Erypo (Epoetin Alfa) - Genotropin (Somatropin) - Herceptin (Trastuzumab) - Humira (Adalimumab) - Neulasta (Pegfilgrastim) - Neupogen (Filgrastim) - Remicade (Infliximab) - Rituxan/MabThera (Rituximab) Biologics and Biosimilars" report examines companies manufacturing biologic and biosimilar equipment and supplies in the world. Companies covered include: - AbbVie, Inc - Abbott Laboratories - Actelion Ltd - Amgen, Inc - Amoytop Biotech Co, Ltd - Anhui Anke Biotechnology (Group) Co, Ltd - Apotex, Inc - Astellas Pharma, Inc - AstraZeneca - Bayer AG - Beijing Four Rings Biopharmaceuticals - Bharat Serums and Vaccines Limited - Bio, Inc - Biocon Ltd - Biogen Idec, Inc - Bioton SA - Boehringer Ingelheim Pharmaceuticals, Inc - Bristol-Myers Squibb, Co - Celgene Corporation - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Elan Corporation, PLC - Eli Lilly & Co - Gideon Richter - Gilead Sciences, Inc - GlaxoSmithKline PLC - Hospira, Inc - Intas Pharmaceuticals Limited - Johnson & Johnson - Merck & Co, Inc - Mylan, Inc - Novartis AG - Pfizer, Inc - Roche Holdings AG - Sandoz International GmbH - Sanofi - Stada Arzneimittel Aktiengesellschaft - Teva Pharmaceutical Industries Limited - Watson Pharmaceuticals, Inc For more information visit http://www.researchandmarkets.com/research/jh...logics_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Corporate Reputation of Pharma in 2012: The Patient Perspective on 29 of the World's Leading Pharma Companies
M2 - Fri May 10, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vttz4c/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma in 2012: The Patient Perspective" report to their offering. A global survey of the views of 600 international, national, and regional patient groups on the corporate reputation of the pharma industry and 29 leading pharma companies Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients, recasting their companies as more patient-centric. PatientView is therefore pleased to ANNOUNCE THE RELEASE of the latest version of its annual review. - A global survey, conducted mid-November to mid-December 2012, exploring the views of 600 international, national, and regional patient groups from 56 countries (72% from Europe) and differing specialties - Patient group feedback on the corporate reputation of the pharma industry during 2012. - Patient group feedback provides rankings of 29 leading pharma companies f
Pharmaceutical Industry in China Report: 2013 Edition
M2 - Tue Apr 16, 5:28AM CDT
Research and Markets has announced the addition of the "Pharmaceutical Industry in China" report to their offering. Aruvian's R'search's report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc. The report also analyzes the Chinese pharmaceutical industry through three frameworks - a SWOT analysis, a PEST analysis, and a Porter's Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China's Pharmaceutical Industry. Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese
(0)
(0)